Collaborating on Treatment
Biomanufacturing and biotechnology companies team up to develop COVID-19 treatment
Biomanufacturing company WuXi Biologics – where chemistry alumnus Richard Soll has held a senior vice president role for nine years – is partnering with Vir Biotechnology to develop a coronavirus treatment. Research and development will take place in Worcester where WuXi is creating a manufacturing facility. It marks the company’s first site in the United States. WuXi and Vir Biotechnology plan on researching SARS antibodies to see if they could function as a potential treatment for COVID-19.
March 24, 2020
